Click here for more details: http://bit.ly/GFP2bm

TessArae GeneCipher™ targeted sequencing assays provide unmatched performance for genetic disease testing in a microarray-based format. Through proprietary assay design and analysis algorithms, TessArae gives you the power to perform comprehensive carrier screening and complex genetic disease testing that is FASTER, EASIER AND LESS EXPENSIVE than Sanger or Next-Gen sequencing. Hundreds of mutations in multiple genes in less than one day with results provided as a list of detected mutations, eliminating the labor-intensive bioinformatics burden.

Please join us for this all-day event with great topics and numerous national healthcare leaders confirmed as speakers

Saturday, October 22, 2011
8:15am – 6:00pm
“At the intersection of policy, implementation, and innovation in the healthcare industry”

Jon M. Huntsman Hall
3730 Walnut Street
Philadelphia, PA 19104-3615

Click here for full details.

Click here to read more

More information at the ACMG Conference Website.

18th International Molecular Medicine Tri-Conference – CHI’s flagship event

ATTEND. DISCOVER. APPLY. The one scientific event for cutting-edge research, trends and analysis. The future holds great promise for molecular medicine, however the demand for results today is ever mounting, from both patients and businesses alike.  The Molecular Med Tri-Con is the place to find the tools to turn ‘someday’ into ‘now’.

Click here for more details: http://bit.ly/fWbACT

Link to award

Kazerin-based Galil Genetic Analysis will next month launch the Affymetrix-made chip, according to officials from both companies.

GGA CEO Yoram Plotsky told BioArray News this week that the two firms have recently finished developing the assay, called the OncoGenetics RDMGGA 1.0 Re-sequencing Chip. It is designed to enable researchers to simultaneously sequence 11 genes and detect more than 3,300 known disease-causing mutations in one test.

Genes included in the test are BRCA1, BRCA2, APC, MUTYH, MLH1, MSH2, MSH6, TP53, PTEN, P16, and KRAS. The chip is in the final stage of validation and will become available next month in Israel, Plotsky said.

Read the full article on the GenomeWeb Website.

The Virginia Biotechnology Association (VABIO), formed in 1992, is the premier statewide non-profit trade association representing the life sciences industry in the Commonwealth of Virginia. Nearly 200 member organizations have joined forces to make VABIO an effective advocate for the biopharmaceutical and device industries before federal, state and local policy-makers.

http://vabio.org/board-of-directors/

TessArae will be in attendance at the 60th Annual Meeting of the American Society of Human Genetics meeting in Washington, DC on November 2-6, 2010.  If you would like to speak to us, please contact us at: http://www.tessarae.com/contact.html.

The TessArae Resequencing Diagnostic Microarray technology will also be discussed in a poster by Galil Genetic Analysis (GGA):

518/T A Novel resequencing Diagnostic Microarray: RDMGGA1.0 chip, customized to diagnose mutations in patients with Breast, Ovarian, Colon, Skin and Multiple Cancers. D. Bercovich1, y. Plotsky2, T. Guy2, S. Allon- Shalev3, AM. Lichanska4, LA. Borsuk4, C. Tibbetts4. 1) Human Genetic Lab, Tel Hai Academic College, Israel; 2) Galil Genetic Analysais (GGA), Kazarin 12900, Israel; 3) The Institute for Genetics, Ha’Emek Medical Center, Afula 18101, Israel; 4) TessArae, Potomac Falls, VA 20165 USA.
Despite the remarkable progress in identifying the genes causing the most common inherited cancers, current diagnostic algorithms do not incorporate all genes and known mutation analysis in the clinical evaluation of affected patients and relatives. In addition, the large genes size and the lack of highly predominant mutational hotspots for most populations frequently make mutation detection in these cancer genes outstandingly challenging, which is costly and time consuming. The interpretation is even more complex as a result of poor studies of gene-gene interactions and genotype-phenotype relationships. To fulfill this technological gap, we developed a new custo- mized resequencing gene chip (RDMGGA1.0) that is focused on 11 genes: BRCA1, BRCA2, APC, MUTYH, MLH1, MSH2, MSH6, TP53, PTEN, P16 and KRAS simultaneously, in a single assay, with high call rate and accuracy. probes were designed to identify each base for all exons, 20 bases of intronic sequence bordering exons in the main tiles, and 3320 most frequent mutations were subtiled. The array uses the Affymetrix resequencing plat- form. Novel software was developed by TessArae for the data analysis. Amplicons were hybridized to the chip, and nucleotide detection was vali- dated by standard capillary sequencing methods. Hybridization of amplicons with the chip produced high nucleotide sequence readout for all 11 genes in a single assay, with an automated call rate of over 98%. The accuracy of nucleotide calls was 99.99% when compared with capillary sequencing. The new resequencing chip enables efficient analysis of 11 genes with a high call rate and accuracy in one assay, and identifies disease-causing mutations.

GeneDx is a premier genetic testing company that specializes in rare hereditary disorders. In 2008 the scientific team determined that they needed to update their testing method for Noonan Syndrome to enhance their competitive position in the market, and engaged in discussions with TessArae to explore an alternative targeted resequencing technology to their conventional (Sanger) sequencing approach.

GeneDx’s Challenge

In 2008 GeneDx was facing a shifting competitive landscape in which new companies were introducing tests for Noonan Syndrome that pushed price and turn-around-time boundaries. GeneDx wanted to maintain its leadership position in this market, so it evaluated new technologies to replace the existing test, which analyzed 45 amplicons by conventional (Sanger) sequencing. Conventional (Sanger) sequencing had several shortcomings:
•    Expensive to sequence and analyze 45 amplicons
•    Long time from Sample to Results
•    Required very clean amplicons

Download Full Case Study (PDF)